CoChat

Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review

Navarese, Eliano P., Kołodziejczak, Michalina, Kereiakes, Dean J., Tantry, Udaya S., O'Connor, Christopher, Gurbel, Paul A. · 2016 · Annals of Internal Medicine

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Abstract

Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) are an emerging therapy for dyslipidemia. Acute coronary events induce a dynamic increase of PCSK9 levels that may play a role in plaque vulnerability of both culprit and nonculprit coronary vessels. Growing evidence highlights a potential key role of PCSK9 antibodies in managing acute coronary syndrome. This review describes the influence of PCSK9 antibodies on plaque composition and instability, as well as the pharmacokinetic profile and the potential anti-inflammatory and antithrombotic mechanisms associated with PCSK9 inhibition that may confer benefits during the early phase of acute coronary syndrome. The authors posit a rationale for the use of PCSK9 antibodies in patients with acute coronary syndrome and highlight the need for further investigation in this area.

Overview

Integrity signals

Registry

Crossref · 10.7326/m15-2994

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. Virmani R, 1999, Thromb Haemost, 82, 1

Cited by

See all 77

Metadata

Authors
Navarese, E. P., Kołodziejczak, M., Kereiakes, D. J., Tantry, U. S., O'Connor, C., & Gurbel, P. A.
Affiliations
  • Inova Fairfax Hospital (US)
  • From Heinrich Heine University, Düsseldorf, Germany; Systematic Investigation and Research on Interventions and Outcomes MEDICINE and Inova Heart and Vascular Institute, Fairfax, Virginia; Collegium Medicum in Bydgoszcz, University of Nicolaus Copernicus, Toruń, Poland; and Christ Hospital Heart and Vascular Center/Lindner Research Center, Cincinnati, Ohio.
Venue
Annals of Internal Medicine
Published
2016-05-03
Volume
164
Issue
9
Pages
600-607
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2305945749
Cited by
77
References
60
Citations by year
2026: 3 · 2025: 3 · 2024: 10 · 2023: 7 · 2022: 3 · 2021: 8 · 2020: 7 · 2019: 5 · 2018: 10 · 2017: 8 · 2016: 11
FWCI
2.25
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Annals of Internal Medicine
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
PCSK9 inhibitors, monoclonal antibodies, acute coronary syndrome, atherosclerotic plaque vulnerability, plaque composition, plaque vulnerability, dyslipidemia, pharmacokinetics, anti-inflammatory mechanism, antithrombotic mechanism
MeSH terms
Proprotein Convertase 9, PCSK9 Inhibitors, Anti-Inflammatory Agents, Antibodies, Monoclonal, Fibrinolytic Agents, Humans, Immunologic Factors, Lipoproteins, LDL, Recurrence, Time Factors, Acute Coronary Syndrome, Plaque, Atherosclerotic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.